Quirk Gerald E 4/A
4/A · Syros Pharmaceuticals, Inc. · Filed Dec 21, 2020
Insider Transaction Report
Form 4/AAmended
Quirk Gerald E
Chief Legal Officer
Transactions
- Award
Stock Option (right to buy)
2016-09-27+35,000→ 35,000 totalExercise: $13.30Exp: 2026-09-26→ Common Stock (35,000 underlying)
Footnotes (2)
- [F1]This option was inadvertently omitted from Mr. Quirk's original Form 4 filed on September 29, 2016.
- [F2]This option vests upon the earlier of (i) the achievement of specified performance-based criteria, as determined by the Issuer's Board of Directors, and (ii) September 26, 2022, subject to Mr. Quirk's continued service as an employee through the vesting date.